Improving Pa-ent Outcomes with Research: The Appliance of Science NIHR UCL Hospitals Biomedical Research Centre

Transcription

1 Improving Pa-ent Outcomes with Research: The Appliance of Science NIHR UCL Hospitals Biomedical Research Centre Bryan Williams MD FRCP FESC FAHA Professor of Medicine and BRC Director 29/08/2013

2 Creating Health and Wealth World Class Universities Unique NHS Innovation and Enterprise Improved Patient Outcomes National Institute for Health Research (NIHR)

3 Challenges in the Biomedical Research Pipeline o Cultural change in Universities o Embracing and Rewarding Enterprise o Regulatory Challenges o Skills Shortage o Lack of Co-ordinated infrastructure o Need for Genomics at scale o Need to Leverage Clinical Data o Need for open industrial partnership

4 Drug Development at Risk Need for a New Model for Partnership with Industry Pharmaceutical Industry R&D Productivity

5 Discovery, Translation, Innovation, Enterprise NIHR Comprehensive Research Network NIHR Biomedical Research Centres BRC Academic Health Science Centres and Networks University Discovery Science Target Validation Patient and BioInformatics Genomics Phenome Centre

6 Biomedical Research Centres Major Research Infrastructure investment ( 100m over 5 years); Partnership between University biomedical Science and the NHS; Focus on improving the translation of world class fundamental research into clinical care unleashing the potential of our leading Universities and the NHS; Focus on reinvigorating the UK bioscience industry by providing the infrastructure to foster partnerships with SMEs and Pharma; Focus on experimental medicine early phase new drugs, new diagnostics and therapeutic innovation for our patients - first; Seamless transition from early phase research to clinical adoption and diffusion across the NHS via Academic Health Science Partnerships; National bioresourcing and informatics genomics, proteomics real world data linkage unparalleled world-wide.

7 UCL Hospitals Focus on Experimental Medicine Education & Capacity Building in Experimental Medicine Cancer Cardiometabolic Infection, Immunity, Inflammation Neurosciences NHS Patients UCL Science

8 What is Experimental Medicine? Investigation undertaken in humans, relating where appropriate to model systems, to identify mechanisms of pathophysiology or disease, or to demonstrate proof-of-concept evidence of the validity and importance of new discoveries or treatments. Medical Research Council Usually early phase human studies up to phase IIa, but experimental medicine can be mechanistic studies embedded within later phase studies.

9 Experimental Medicine and the Translational Pathway at UCL Innovation Office UCLB / TRO / UCL Enterprise Accelerate translation UCL Discovery / Target Validation First in man evaluation, safety, proof of concept, mechanisms BRC CRF CTU UCLP Adoption Efficacy Diffusion Implementation / Patient Outcomes UCLP Industrial Collaboration Sir Francis Crick Institute Yale UCL Partnership Cross BRC/BRU Collaboration MRC Chapter e Health Reverse Translation Creating Health and Wealth

10 Discovery Proof of concept UCL Discovery Engine and the Sir Francis Crick Institute BRC and BRUs UCLH-UCL NIHR BRC Cardiometabolic Cancer Infection and Inflammation Neuroscience GOSH/Child Health NIHR BRC Moorfields/Ophthalmology NIHR BRC UCLH-UCL NIHR BRU Dementia

11 Early Phase Clinical Research Facilities Proof of concept / mechanisms Dedicated CRF Embedded within the hospital Complex Phase I/II study capability New Neuroscience CRF at Queen Sq.

12 UCL Partners: Adoption & Translation Largest Academic Health Science Network in Europe; Translating, Adopting and Delivering Biomedical Innovation at scale; Facilitating and Streamlining later phase clinical trials; Evaluation at scale

13 Big Data leveraging the research potential of our patient populations UCL FARR Institute is one of four E-Health Informatics Research Centres funded by the MRC and partners. Aims to bring together its partners world-class clinical science, informatics expertise and educational strengths to establish an international centre of excellence in innovative health informatics research, and maximise translational impact for patient benefit. National Health Informatics Collaborative (NHIC) Big 5 BRCs (UCL, Imperial, Kings, Oxford, Cambridge) combine to leverage patient data for researcg

14 Context for Change.. NHS Innovation for Health and Wealth Agenda; Major Government investment in UK Bioscience; Key emphasis on leverage and wealth creation; Industrial engagement Pharma, MedTech, Biotech and SMEs inward investment Enterprise and Entrepreneurship from within; Innovation in Health Care; the value proposition

15 NIHR University College London Hospitals Biomedical Research Centre

16 New partnerships UCL NHS UCLH BRCs

17 What does all of this mean for patients? First and often unique access leading edge developments in medicine; Recruitment and retention of world-leading clinicians/academics; A culture of excellence and academic rigor that permeates all that we do; An opportunity to tackle fundamental challenges in medicine: Examples: - Treatment Resistant Cancer - Emerging antibiotic resistance / HIV and epidemic viruses - Best exploitation of developments in imaging - Treatments for Dementia - Better treatment for Stroke

18 Public and Patient Involvement We are looking for opportunities to engage with the public and our patients this is your BRC o o o o o Help and advice in designing our research projects Help and advice in producing appropriate communications with patients and the public Help in developing better ways to communicate our research results and its impact Help with media work Help in getting more people involved in research Contact Rosamund Yu Telephone: rosamund.yu@ucl.ac.uk Website:

19

20 NIHR University College London Hospitals BRC in the Media

21 NIHR University College London Hospitals BRC in the Media

22 Biomedical Research Centre Summary Partnership between UCL and the NHS (UCL Hospitals) Translating Discovery into patient care: Complex Phenotyping, Early Phase Evaluation (I/II) and Evaluating Mechanisms of Disease (II-IV); Partnership with UCLPartners Adoption and Implementation at scale (III/IV); A strong spirit of Innovation and Entrepreneurship; A new culture of Collaboration and Partnership with industry creating health and wealth a unique opportunity; Aligned and explicitly supported by UK Government strategy and funding coordinated by the NIHR Office for Clinical Research Infrastructure (NOCRI) nihr.ac.uk/infrastructure/nocri